Menu
ABOUT OIC/LAXATIVE FAILURE: WHAT’S NEXT?
Laxatives are often not effective for OIC1
Real-world data suggest substantial treatment needs2
In a cross-sectional patient survey
conducted in the United States, Canada, Germany
and the United Kingdom in patients with OIC (N=493)
conducted in the United States, Canada, Germany
and the United Kingdom in patients with OIC (N=493)
%
did not respond adequately to the use of at least 1 laxative agent within the previous 2 weeks2
27%
did not respond adequately to the use of at least 2 laxative agents from 2 or more different classes at least 4 times each within the previous 2 weeks2
Laxatives can be effective for functional constipation, which may be caused by:3,4
Laxatives do not target the cause of OIC
—opioids binding to mu-receptors in the bowel5,6
OIC, opioid-induced constipation.
WHEN LAXATIVES DON’T HELP,
CONSIDER A TREATMENT THAT CAN
Treat the underlying cause of OIC.
References 1. Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386-1395. doi:10.1111/nmo.12417 2. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269-281. doi:10.2147/CEOR.S61602 3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(suppl B):16B-21B. 4. Pergolizzi Jr JV, Raffa RB, Pappagallo M, et al. Peripherally acting U-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Pref Adher. 2017;11:107-119. 5. Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Design Dev Ther. 2015;9:2215-2231. doi:10.2147/DDDT.S32684. 6. MOVENTIG Summary of Product Characteristics. Accessed May 2022. https://www.medicines.org.uk/emc/medicine/30483/smpc.
VIEW PRESCRIBING INFORMATION 
PRESCRIBING INFORMATION (prepared August 2021)
Moventig® (naloxegol oxalate) 12.5mg and 25mg film-coated tablets
Consult Summary of Product Characteristics (SmPC) before prescribing.
Indication: Opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s) (concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the previous 2 weeks).
Dosage and administration: Recommended 25 mg once daily. Take on empty stomach at least 30 minutes prior to first meal of day or 2 hours after first meal of day. Crushed tablets can be mixed with water (120ml) and drunk immediately or administered via a nasogastric tube (CH8 or greater). Renal impairment: Moderate or severe renal impairment starting dose 12.5mg. Discontinue if side effects impact tolerability. Increase to 25mg if well tolerated. Hepatic impairment: Use in severe hepatic impairment not recommended. Moderate CYP3A4 inhibitors: Starting dose 12.5mg, can be increased to 25mg if well tolerated. Paediatric population (<18 years): Safety and efficacy not yet established.
Adverse effects: Consult SmPC for full list of side effects. Very Common: Abdominal pain, diarrhoea. Common: Nasopharyngitis, headache, flatulence, nausea, vomiting, hyperhidrosis. Uncommon: Opioid withdrawal syndrome. Not known: Hypersensitivity, Gastrointestinalperforation.
Contraindications: Hypersensitivity to active substance or any of the excipients or any other opioid antagonist. Patients with known or suspected gastrointestinal (GI) obstruction or patients at increased risk of recurrent obstruction. Patients with underlying cancer who are at heightened risk of GI perforation, such as those with underlying malignancies of gastrointestinal tract or peritoneum, recurrent or advanced ovarian cancer or vascular endothelial growth factor (VEGF) inhibitor treatment. Concomitant use with strong CYP3A4 inhibitors.
Warnings and precautions: Cases of gastrointestinal perforation have been reported in the post-marketing setting, including fatal cases when naloxegol was used in patients who were at an increased risk of gastrointestinal (GI) perforation. Naloxegol must not be used in patients with known or suspected gastrointestinal obstruction or in patients at increased risk of recurrent obstruction. Use with caution in patients with any condition which might result in impaired integrity of the gastrointestinal tract wall. Advise patients to discontinue therapy and promptly report if unusually severe or persistent abdominal pain develops. Use with caution in patients with clinically important disruptions to the blood brain barrier and observe for potential CNS effects. Discontinue if interference with opioid-mediated analgesia or opioid withdrawal syndrome occurs. Use with caution in patients taking methadone. If opioid withdrawal syndrome is suspected the patient should discontinue Moventig and contact their physician. Use with caution in patients with a recent history of myocardial infarction, symptomatic congestive heart failure, overt cardiovascular (CV) disease or with a QT interval of ≥500msec. Use with caution in OIC patients with cancer-related pain. Use of naloxegol with another opioid antagonist (e.g. naltrexone, naloxone) should be avoided.
Use in pregnancy and lactation: Not recommended.
Legal category: POM.
Marketing Authorisation numbers: Moventig 12.5mg and 25mg tablets (ROI: EU/1/14/962/001-011),(GB: PL GB 50262/004&5)
Further information available on request from the Marketing Authorisation holder: Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands.
For the United Kingdom:
NHS cost: Moventig 12.5mg, 30 tablets, £55.20; Moventig 25mg, 30 tablets, £55.20.
NHS cost: Moventig 12.5mg, 30 tablets, £55.20; Moventig 25mg, 30 tablets, £55.20.
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com
For the Republic of Ireland:
Adverse Events should be reported. Information about adverse event reporting can be found at www.hpra.ie. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com
OIC, opioid‐induced constipation.
This program is best viewed on a device with a higher screen resolution. Some content may not be optimally presented.